Related Experiment Videos
Preliminary experience with double-phase SPECT using Tc-99m sestamibi in patients with hyperparathyroidism
D R Neumann1, C B Esselstyn, E Y Kim
1Department of Nuclear Medicine, Cleveland Clinic Foundation, Ohio 44195-5074, USA.
Clinical Nuclear Medicine
|April 1, 1997
Summary
Double-phase Technetium-99m sestamibi SPECT imaging shows promise for parathyroid pathology. This nuclear medicine technique is particularly effective for detecting hyperfunctioning parathyroid tissue in patients with recurrent hyperparathyroidism.
Area of Science:
- Nuclear Medicine
- Radiopharmacology
- Endocrinology
Background:
- Parathyroid pathology imaging is an evolving field.
- Technetium-99m sestamibi is a potential alternative to Thallium-201 for parathyroid scintigraphy.
Purpose of the Study:
- To evaluate the efficacy of a dual-phase Technetium-99m sestamibi SPECT technique for parathyroid imaging.
Main Methods:
- Sixty-one hyperparathyroidism patients underwent dual-phase SPECT imaging 15 minutes and 2 hours post-injection of Tc-99m sestamibi.
- A positive scan indicated persistent focal uptake on delayed images.
Main Results:
- The technique identified 55% of adenomas in previously unoperated patients and 91% in reoperative patients.
- It correctly identified normal parathyroid glands in 92% of unoperated and 88% of reoperative patients.
Conclusions:
- Preliminary findings suggest double-phase Tc-99m sestamibi SPECT is a valuable tool for preoperative parathyroid imaging.
- The technique is especially useful for detecting recurrent or persistent hyperparathyroidism post-surgery.